Profile data is unavailable for this security.
About the company
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide (CPP) technology platform. The Company’s lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver tissue frataxin (FXN), an essential protein, to the mitochondria of patients with Friedreich's ataxia (FA). FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. Its CPP platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, has the potential to enable the treatment of other rare and orphan diseases. The Company intends to use its proprietary platform to target additional orphan indications characterized by deficiencies in or alterations of intracellular content or activity.
- Revenue in USD (TTM)0.00
- Net income in USD-132.00m
- Incorporated2005
- Employees65.00
- LocationLarimar Therapeutics IncTHREE BALA PLAZA EAST. SUITE 506BALA CYNWYD 19004United StatesUSA
- Phone+1 (617) 622-4003
- Fax+1 (302) 655-5049
- Websitehttps://larimartx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lexeo Therapeutics Inc | 0.00 | -104.97m | 516.02m | 72.00 | -- | 3.21 | -- | -- | -2.70 | -2.70 | 0.00 | 2.20 | 0.00 | -- | -- | 0.00 | -66.08 | -- | -76.72 | -- | -- | -- | -- | -- | -- | -- | 0.0084 | -- | -- | -- | -48.11 | -- | -- | -- |
| Rocket Pharmaceuticals Inc | 0.00 | -223.12m | 521.13m | 202.00 | -- | 1.88 | -- | -- | -2.01 | -2.01 | 0.00 | 2.56 | 0.00 | -- | -- | 0.00 | -52.00 | -42.96 | -56.68 | -46.18 | -- | -- | -- | -- | -- | -- | 0.0713 | -- | -- | -- | 13.77 | -- | -56.75 | -- |
| Fulcrum Therapeutics Inc | 0.00 | -74.88m | 524.14m | 55.00 | -- | 1.50 | -- | -- | -1.18 | -1.18 | 0.00 | 5.24 | 0.00 | -- | -- | 0.00 | -23.89 | -30.35 | -24.84 | -32.48 | -- | -- | -- | -344.07 | -- | -- | 0.00 | -- | -100.00 | -- | -669.97 | -- | -25.21 | -- |
| Zura Bio Ltd | 0.00 | -62.52m | 559.56m | 30.00 | -- | 3.90 | -- | -- | -0.6686 | -0.6686 | 0.00 | 1.66 | 0.00 | -- | -- | 0.00 | -39.10 | -- | -49.83 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 34.45 | -- | -- | -- |
| Allogene Therapeutics Inc | 0.00 | -212.02m | 568.57m | 226.00 | -- | 1.79 | -- | -- | -0.981 | -0.981 | 0.00 | 1.41 | 0.00 | -- | -- | 0.00 | -41.21 | -31.11 | -43.96 | -33.14 | -- | -- | -- | -1,187.06 | -- | -- | 0.00 | -- | -76.84 | -- | 21.29 | -- | -57.62 | -- |
| Design Therapeutics Inc | 0.00 | -67.45m | 569.64m | 55.00 | -- | 2.85 | -- | -- | -1.19 | -1.19 | 0.00 | 3.51 | 0.00 | -- | -- | 0.00 | -28.49 | -18.88 | -29.66 | -19.44 | -- | -- | -- | -98,925.22 | -- | -- | 0.00 | -- | -- | -- | 25.84 | -- | -- | -- |
| Larimar Therapeutics Inc | 0.00 | -132.00m | 570.78m | 65.00 | -- | 3.39 | -- | -- | -1.93 | -1.93 | 0.00 | 1.62 | 0.00 | -- | -- | 0.00 | -64.96 | -45.05 | -76.53 | -50.22 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -118.15 | -- | -7.58 | -- |
| Perspective Therapeutics Inc | 1.08m | -106.31m | 588.94m | 138.00 | -- | 1.59 | -- | 547.85 | -1.46 | -1.46 | 0.0147 | 3.26 | 0.0031 | -- | 5.43 | 7,789.86 | -31.00 | -- | -33.37 | -- | -- | -- | -9,889.68 | -- | -- | -- | 0.0067 | -- | 1.39 | -- | -109.13 | -- | -- | -- |
| Replimune Group Inc | 0.00 | -314.85m | 592.05m | 479.00 | -- | 2.71 | -- | -- | -3.44 | -3.44 | 0.00 | 2.64 | 0.00 | -- | -- | 0.00 | -67.19 | -33.04 | -75.03 | -35.07 | -- | -- | -- | -- | -- | -- | 0.2565 | -- | -- | -- | -14.60 | -- | 0.4456 | -- |
| YD Bio Ltd | -100.00bn | -100.00bn | 597.32m | 5.00 | -- | 117.39 | -- | -- | -- | -- | -- | 0.0722 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 1.36 | -- | 0.0124 | -- | 45.76 | -- | -10,509.73 | -- | -- | -- |
| MeiraGTx Holdings PLC | 27.42m | -168.69m | 598.05m | 409.00 | -- | -- | -- | 21.81 | -2.11 | -2.11 | 0.343 | -0.5039 | 0.1121 | -- | 9.01 | 71,960.63 | -69.00 | -30.69 | -121.96 | -38.41 | 41.01 | -- | -615.27 | -428.39 | 0.2235 | -36.10 | 2.21 | -- | 137.42 | 20.15 | -75.89 | -- | -11.21 | -- |
| Ocugen Inc | 5.37m | -64.02m | 609.87m | 95.00 | -- | 164.43 | -- | 113.57 | -0.2167 | -0.2167 | 0.0182 | 0.0113 | 0.0899 | -- | -- | 56,526.32 | -107.12 | -79.82 | -153.51 | -95.76 | -- | -- | -1,192.18 | -2,251.08 | -- | -19.41 | 0.8894 | -- | -32.82 | -- | 14.31 | -- | 158.28 | -- |
| Vor Biopharma Inc | 0.00 | -2.45bn | 620.72m | 159.00 | -- | -- | -- | -- | -386.85 | -386.85 | 0.00 | -246.54 | 0.00 | -- | -- | 0.00 | -1,676.47 | -49.21 | -1,891.22 | -52.72 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.8052 | -- | -21.08 | -- |
| Alto Neuroscience Inc | 0.00 | -62.26m | 624.74m | 76.00 | -- | 4.90 | -- | -- | -2.31 | -2.31 | 0.00 | 4.11 | 0.00 | -- | -- | 0.00 | -36.77 | -- | -39.46 | -- | -- | -- | -- | -- | -- | -- | 0.1675 | -- | -- | -- | -69.21 | -- | -- | -- |
Data as of Mar 03 2026. Currency figures normalised to Larimar Therapeutics Inc's reporting currency: US Dollar USD
25.89%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Millennium Management LLCas of 31 Dec 2025 | 5.21m | 6.08% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 3.32m | 3.88% |
| RTW Investments LPas of 31 Dec 2025 | 3.13m | 3.65% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 2.74m | 3.20% |
| AIGH Capital Management LLCas of 31 Dec 2025 | 2.00m | 2.34% |
| Point72 Asset Management LPas of 31 Dec 2025 | 1.46m | 1.71% |
| Citadel Advisors LLCas of 31 Dec 2025 | 1.34m | 1.57% |
| Geode Capital Management LLCas of 31 Dec 2025 | 1.09m | 1.28% |
| DAFNA Capital Management LLCas of 31 Dec 2025 | 939.16k | 1.10% |
| Alyeska Investment Group LPas of 31 Dec 2025 | 927.82k | 1.08% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
